Skip to content

Deoxycholic Acid

FDA-approved product (solution, subcutaneous), marketed as Deoxycholic Acid, Kybella.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Deoxycholic Acid
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Deoxycholic Acid. Its therapeutic class is shown instead.

WHO therapeutic group
Other dermatologicals
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA69.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli19.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae34.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis27.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Deoxycholic Acid with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus

    NCT01899703 · start 2014-03-10

    Registered record
    Registry ID
    NCT01899703
    Conditions
    Cholestasis, Intrahepatic
    Interventions
    GSK2330672; Placebo; Ursodeoxycholic acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-03-10
    Completion
    2015-10-07
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCholestasis, Intrahepatic
    InterventionGSK2330672; Placebo; Ursodeoxycholic acid
    PhasePhase 2
    Registry statusCompleted
  • Patient Experience Study of Deoxycholic Acid Injection

    NCT02007434 · start 2013-12

    Registered record
    Registry ID
    NCT02007434
    Conditions
    Moderate or Severe Submental Fullness
    Interventions
    Deoxycholic Acid Injection; Placebo; Cold Compress; Lidocaine / Epinephrine; Loratadine; Ibuprofen; Compression Chin Strap
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-12
    Completion
    2014-06
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionModerate or Severe Submental Fullness
    InterventionDeoxycholic Acid Injection; Placebo; Cold Compress; Lidocaine / Epinephrine +3 more
    PhasePhase 3
    Registry statusCompleted
  • Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease

    NCT02021110 · start 2013-12

    Registered record
    Registry ID
    NCT02021110
    Conditions
    Polycystic Liver Disease; Polycystic Kidney, Autosomal Dominant
    Interventions
    Ursodeoxycholic Acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-12
    Completion
    2015-10
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycystic Liver Disease; Polycystic Kidney, Autosomal Dominant
    InterventionUrsodeoxycholic Acid
    PhasePhase 2
    Registry statusCompleted
  • Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis

    NCT01904058 · start 2013-08

    Registered record
    Registry ID
    NCT01904058
    Conditions
    PBC; Primary Biliary Cirrhosis
    Interventions
    LUM001; Placebo; Ursodeoxycholic Acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-08
    Completion
    2015-04
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPBC; Primary Biliary Cirrhosis
    InterventionLUM001; Placebo; Ursodeoxycholic Acid
    PhasePhase 2
    Registry statusCompleted
  • Open-Label Pharmacokinetic Study of Final Formulations of ATX-101

    NCT01632917 · start 2012-06

    Registered record
    Registry ID
    NCT01632917
    Conditions
    Healthy
    Interventions
    ATX-101 - U.S.; ATX-101 - EU
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-06
    Completion
    2012-07
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionATX-101 - U.S.; ATX-101 - EU
    PhasePhase 1
    Registry statusCompleted
  • Safety and Efficacy Study of Doxycycline/UrsoDeoxyCholicAcid on Disease Progression in ATTR Amyloidosis

    NCT02016365 · start 2012-02

    Registered record
    Registry ID
    NCT02016365
    Conditions
    Transthyretin Amyloidosis; Cardiomyopathy
    Interventions
    Doxycycline; Ursodeoxycholic acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-02
    Completion
    2014-12
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransthyretin Amyloidosis; Cardiomyopathy
    InterventionDoxycycline; Ursodeoxycholic acid
    PhasePhase 2
    Registry statusCompleted
  • Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil

    NCT01310738 · start 2011-02

    Registered record
    Registry ID
    NCT01310738
    Conditions
    Visceral Leishmaniasis
    Interventions
    Antimoniate of N-methylglucamine; amphotericin B deoxycholate; Liposomal amphotericin B; Liposomal amphotericin B; Antimoniate of N-methylglucamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2011-02
    Completion
    2015-02
    Enrolment
    378

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVisceral Leishmaniasis
    InterventionAntimoniate of N-methylglucamine; amphotericin B deoxycholate; Liposomal amphotericin B; Liposomal amphotericin B +1 more
    PhasePhase 4
    Registry statusTerminated
  • Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat

    NCT01305577 · start 2010-12

    Registered record
    Registry ID
    NCT01305577
    Conditions
    Moderate or Severe Submental Fullness
    Interventions
    Deoxycholic acid injection; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-12
    Completion
    2012-01
    Enrolment
    363

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionModerate or Severe Submental Fullness
    InterventionDeoxycholic acid injection; Placebo
    PhasePhase 3
    Registry statusCompleted
  • Ursodeoxycholic Acid And Cholestasis Of Pregnancy

    NCT01226823 · start 2010-11

    Registered record
    Registry ID
    NCT01226823
    Conditions
    Intrahepatic Cholestasis of Pregnancy
    Interventions
    Ursodeoxycholic Acid; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2010-11
    Completion
    2013-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntrahepatic Cholestasis of Pregnancy
    InterventionUrsodeoxycholic Acid; Placebo
    PhasePhase 3
    Registry statusWithdrawn
  • Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis

    NCT01483248 · start 2010-10

    Registered record
    Registry ID
    NCT01483248
    Conditions
    Liver Cirrhosis; Fibrosis; Liver Disease; Digestive System Disease
    Interventions
    conventional therapy plus MenSC transplantation; Conventional therapy plus placebo treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2010-10
    Completion
    2015-10
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cirrhosis; Fibrosis; Liver Disease; Digestive System Disease
    Interventionconventional therapy plus MenSC transplantation; Conventional therapy plus placebo treatment
    PhasePhase 1 / Phase 2
    Registry statusUnknown
  • Efficacy and Safety Study of TUDCA Compare UDCA to Treatment Chronic Cholestatic Liver Disease-PBC

    NCT01829698 · start 2009-08

    Registered record
    Registry ID
    NCT01829698
    Conditions
    Cholestatic Liver Disease
    Interventions
    tauroursodeoxycholic; ursodeoxycholic acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-08
    Completion
    2014-02
    Enrolment
    199

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCholestatic Liver Disease
    Interventiontauroursodeoxycholic; ursodeoxycholic acid
    PhasePhase 3
    Registry statusCompleted
  • Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat

    NCT00618618 · start 2008-04

    Registered record
    Registry ID
    NCT00618618
    Conditions
    Moderate or Severe Submental Fullness
    Interventions
    Deoxycholic Acid Injection; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-04
    Completion
    2008-12
    Enrolment
    73

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionModerate or Severe Submental Fullness
    InterventionDeoxycholic Acid Injection; Placebo
    PhasePhase 2
    Registry statusCompleted
  • Phase 2 Study for the Treatment of Superficial Lipomas

    NCT00608842 · start 2007-11

    Registered record
    Registry ID
    NCT00608842
    Conditions
    Lipoma
    Interventions
    Deoxycholic Acid Injection; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-11
    Completion
    2010-01
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLipoma
    InterventionDeoxycholic Acid Injection; Placebo
    PhasePhase 2
    Registry statusCompleted
  • Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat

    NCT00618722 · start 2007-08

    Registered record
    Registry ID
    NCT00618722
    Conditions
    Moderate or Severe Submental Fullness
    Interventions
    Deoxycholic Acid Injection; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2007-08
    Completion
    2008-10
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionModerate or Severe Submental Fullness
    InterventionDeoxycholic Acid Injection; Placebo
    PhasePhase 1 / Phase 2
    Registry statusCompleted
  • Effects of Ursodeoxycholic Acid on Graft Recovery Early After Adult Liver Transplantation

    NCT01073202 · start 2005-05

    Registered record
    Registry ID
    NCT01073202
    Conditions
    Liver Transplantation; Ischemia-reperfusion Injury; Cholestasis
    Interventions
    ursodeoxycholic acid; identical-appearing placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-05
    Completion
    2009-01
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplantation; Ischemia-reperfusion Injury; Cholestasis
    Interventionursodeoxycholic acid; identical-appearing placebo
    PhaseNot applicable
    Registry statusCompleted